IJHOSCR
Primary Hyperaldostronisim as Initial Presentation of Adrenal Cortical Carcinoma with Liver Metastasis: A Case Report
Naser Aghamohammadzadeh1, Afsaneh Faraji2, Farshid Bozorgi3, Ismail Faraji4, Majid Moghadaszadeh5
1Assistant Professor, Endocrinology Department, Tabriz University of Medical Sciences, Tabriz, Iran
2Medical Student, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3Anatomical and Clinical Pathologist, Tabriz University of Medical Sciences, Tabriz, Iran
4Internist, fellow of Endocrinology, Tabriz University of Medical Sciences, Tabriz, Iran
5Resident of Internal Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Corresponding author: Majid Moghadaszadeh, MD Internal Medicine Department, Tabriz University of Medical Sciences, Tabriz, Iran E-mail: m_moghadaszadeh@hotmail.com
Tel: +989144141359
Received: 10, Jan, 2013 Accepted: 6, Feb, 2013
ABSTRACT
Adrenocortical carcinoma (ACC) is a rare tumor and usually a fatal disease which can develop at any age in either sex. Differential diagnosis between malignant and benign adrenal mass is not easy which leads to significant clinical challenge for optimal treatment. Here we report a 22-year-old woman diagnosed with primary hyper aldostronism initially but disease relapsed during six months and magnetic resonance imaging revealed tumor with metastasis to the liver.
KEY WORDS: Adrenocortical carcinoma, Liver metastases, Surgery
INTRODUCTION
Adrenal cortical carcinoma (ACC) is a very rare heterogeneous tumor which represents 0.02% all neoplasias and its global estimated incidence is 0.5- 2 per every 1000,000 persons each year.1 There is a bimodal age distribution with two peaks in the first and forth to fifth decades.2, 3 Its etiology is unknown. The majority of cases are incidental diagnosis of advanced stage disease with metastasizes. Tumors of adrenal gland are classified as functioning and non-functioning tumors. Functional tumors occur in 59.3%-62% of cases and they may produce cortisol (30%-40%), androgens (20%-30%), estrogens (6%-10%) or aldostron (2%- 2.5%) and mixed pattern of hormone production is seen in 24%-35% of patients.2, 4, 6 This hormone production may trigger patient’s symptoms; and they depend on patient’s age and on which
hormones are over produced. Although it is potentially curable at early stages, only about 30% of these malignancies are confined to the adrenal gland when they are diagnosed, because these tumors tend to be found years after they began growing, they have opportunity for near and distant metastases and this aggressive behavior leads to its poor prognosis. The most common sites of distant metastases are the liver (48%-85%), lung (30%- 60%), lymph nodes (7%-20%) and bone (7%-13%).4, 7, 8 We present a case of functioning adrenal cortical carcinoma in a 22-year-old female patient with liver metastases and a retroperitoneal mass which recurred after right adrenal surgical resection during six months. In the article, the symptoms associated with hormones produced by the tumor, diagnostics and treatment with regard to the progression of disease have also been discussed.
CASE REPORT
A 22-year-old female patient with a 4-month history of weakness and tachycardia referred to Imam Reza hospital in Tabriz because of intensity of symptoms and loss of consciousness. The blood examination revealed decreased levels of potassium; 2.7 mEq/L and her blood pressure was 190/100 mmHg, she just received emergency agents as outpatient. After three months, symptoms flared up and the patient was admitted to the department of internal medicine. A detailed past medical history of the patient was taken; hypertension during last six months and preeclampsia in her prior pregnancy were detected. No family history of malignancies found. In her review of systems; weight loss (7kg during last four months), weakness, headache, tachycardia, nocturia, polyuria, polydipsia and frequency were found and there was no significant history of abdominal pain, vomiting, urinary incontinence or fever. Mucosal dehydration and positive trousseau test were points in general and physical examination. Before hospitalization she obtained atenolol 50mg/24h for hypertension. Liver and renal function tests, complete blood count and urine 24h analysis were within normal limits. Urine complete examination was negative for albumin and sugar, and in microscopic analysis; WBC: 15-16 and epithelial cell: 27-28 was reported, No crystals or casts were detected and urine culture was negative. Serum potassium was 2.9mEq/L and serum Ca ion was 0.87mmol/L. Arterial blood gas examination indicated metabolic alkalosis (PH=7.54, PCO2=34.7, HCO3=29). ECG and chest x-ray were normal. Blood measurements of plasma aldostron and rennin after one hour upright standing posture in the morning were: aldostron=350 units, rennin=0.9 units. A captopril Suppression Test (CST) did not result in aldostron suppression. In order to confirm the first diagnosis, an abdominal spiral computed tomography was performed but there was no evidence of any lesions in liver, kidneys and adrenal glands. Despite the previous oral and later intravenous potassium supplementation of up to 40mEq/24h, potassium level was low and on the 10th day of hospitalization it was 3.2mEq/L. Calcium channel blockers, ß-blockers and potassium sparing diuretics were added to the treatment and resulted
in blood pressure decrease to 140/80mmHg on the last day of hospitalization. The patient was discharged from hospital but symptoms recurred after a week. In magnetic resonance imaging (MRI) of adrenal glands with IV contrast, a mass measuring 53×25x46 mm in size at the posterior aspect of inferior vena cava and medial side of liver just above right adrenal gland confirmed an adrenal gland tumor (Fig.1). The patient underwent exploratory laparotomy with excision of right adrenal gland. The tumor had extended behind IVC, no invasion to adjacent organs or metastasis to lymph nodes was noted during the operation. Per- operative finding was a mass of about 6×5.5x1.5 cm.
Avanto MR B15
STUDY 1 1/4/2010
HFS +LPH
S
9:23:09 AM 10 IMA 7 / 20
+
R
P
MF 1.21
10cm
TR 217.0
TE 4.8
TA 30.28*2
TP H
BW 140.0
SP H100
p2 M/NORM/DIS2D
SL 6.0
FoV 380*380
Histopathological examination revealed adrenal tissue with a cortical adenoma with areas of hemorrhage and necrosis, composed of cells with granular cytoplasm, mild and focal nuclear pleomorphism and occasional mitosis. After the surgical intervention, she was discharged uneventfully. Then she was followed-up irregularly due to pregnancy. Signs and symptoms have been revealed for six months, until the end of her first trimester (16th week), meanwhile she had flaring of hypertension and hypokalemia during anesthesia for McDonald’s operation. Followed-up MRI showed no evidence of recurrent tumor at right side, even size or configuration of left side adrenal gland was normal. Her poor follow-up during pregnancy resulted in recurring hypertension and hypokalemia during cesarean section. On post operative control MRI of abdomen one year after right adrenalectomy, a round solid mass at the site
of removed adrenal gland measuring 56×53 mm on diameter was seen. The mass involved the inferior aspect of the liver and probably superior anterior aspect of the right kidney. These findings indicated relapse of the removed adrenal tumor (Fig. 2). Liver needle biopsy was performed and proved liver tissue with relatively normal parenchymal cells and small focus of atypical cells. Primary surgery’s slides reviewed; pathological examination revealed a cream-brown mass about 3.5x3 cm with hemorrhagic and necrotic areas. On microscopic assessment, neoplastic proliferation of adrenocortical cells in a diffuse pattern sometimes with severe pleomorphism, tumor cell necrosis with occasionally mitoses more than 5/50HPF was seen.
10cm
Tumoral cells also invaded the capsule, so according to Weiss criteria for malignancy, (Nine histological criteria of Adrenal Cortical Carcinoma: 1. Nuclear grade C Fuhrman III/I 2. Mitotic rate 5/50 hpf. 3. Abnormal mitosis 4. < 25% clear cells 5. 1/3 diffuse architecture 6. Necrosis 7. Venous invasion 8. Sinusoidal invasion 9. Capsular invasion),9 this neoplasm had five of nine criteria which was compatible with adrenal cortical carcinoma (Fig. 3 and Fig. 4).
The patient was discussed in tumor board and surgery planned for her followed by adjuvant treatment; surgery versus chemotherapy with mitotane. The Patient underwent surgery again with resection of right recurring adrenal tumor, liver right lobe segmental lobectomy, cholecystectomy and resection of retroperitoneal mass was done under general anesthesia. Histopathologic assessment of second surgical specimens showed
segmental lobectomy of right hepatic lobe (14×12×12 cm) and retroperitoneal mass resection (5x5x4 cm) also showed the same microscopic features of primary adrenal cortical tumor composed of large eosinophilic cells with highly atypical nuclei arranged in peritheliomatous and diffuse pattern with extensive necrosis (Fig. 5 and Fig. 6).
DISCUSSION
We present a case of disseminated ACCs, which is a rare neoplasm occurring with a frequency of 1-2 cases per million per year, and the prevalence has been variably reported at 2 cases per one population per year worldwide, accounting for 0.05% to 0.2% of all cancers.1º Etiology of adrenal cortical carcinoma is still unclear, but roles of genetic and environmental factors, e.g. pesticide pollution, have been largely considered. It is more frequent in women (58.6%) than in men (41.4%) 11. ACC has poor prognosis and the tumor size is still the best single predictor of prognosis. The recommended imaging exams are computed tomography and Magnetic Resonance (MR), but MR is more sensitive, and showed the tumor in our patient. Routine adrenal biopsy is not recommended, because of procedure risk and a limited diagnostic value.12 One review study reported 60% of the tumors as functional tumors13 that may secrete excessive glucocorticoids (Cushing’syndrom), mineralocorticoids and their procedures; including androgens (Virilization) or estrogens (Feminization), as well as aldostrone causing hypertension.14 The non- functioning tumors may present with pain or fullness in the abdomen due to mass effect, weight loss, weakness, fever and myalgias,13 or it may be discovered incidentally during radiographic imagings (CT or MRI) performed for other reasons.15 In rare cases its first manifestations are distant metastases, e.g. to bones, which can cause pathological fractures or bone pain.16 Differentiating between adrenal adenoma and
carcinoma in a small lesion can be challenging, although definitive diagnosis of malignancy in adrenocortical lesions is based on the presence of distant metastasis or local invasion,18 due to this problem we made a delayed diagnosis. Clinical staging of the tumor is essential for treatment plan, as well as prognosis determination. For staging tumor, node and metastasis system (TNM) of the American Joint Committee on cancer should be used; a tumor size of 5 cm or less with no spread to surrounding tissues or to lymph nodes without distant metastasis is classified as stage I. A tumor larger than 5 cm with other stage I characteristics is classified as stage II. Tumor invasion to nearby tissues and/or spread to nearby lymph nodes is classified as stage III and distant metastasis is classified as stage IV.13 Our patient has stage IV disease with a tumor size about 5 cm and distant metastasis to the liver and retroperitoneal mass. Surgery is still the mainstay of treatment for metastatic carcinoma because there is no definitive protocol for chemotherapy. Although mitotan is still the first choice pharmacological treatment, but its therapeutic value is still very controversial and it has not been proved to be effective.17 It is taken orally (35% to 45% absorption) and it has a long half-life (18-159 days). Nausea, vomiting, anorexia, weight loss, diarrhea, lethargy, sedation, dizziness, ataxia, gynecomastia, leucopenia and reversible growth arrest in children are the common side effects of Mitotan therapy.14 Prednisolon in a daily dose of 5-10 mg is used to alleviate symptoms.12
Following the surgeries, our patient received approximately 1 to 6 g mitotan per day for period of one month, but mitotan was later discontinued because of gastrointestinal side effect for the patient; including illeus. Now, cancer relapse by liver metastases has influenced our case physically and emotionally and has reduced life-expectancy of patient.
REFERENCES
1. Kopf D, Goretzki PE, Lehnert H. Clinical managment of malignant arenal tumors. J Cancer Res Clin Oncol. 2001; 127: 143-155.
2. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-55.
3. Stratakis CA, Chrousos GP: Adrenal cancer. Endocrinol Metab Clin North Am 2000; 29:15-25.
4. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003; 169:5-11.
5. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25:914-26.
6. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992; 112:972-979.
7. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-
8. Wajchenberg BL, Albergaria Pereira MA, Medonca BB. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711-36.
9. SILVERBERG’s principles & practice of surgical pathology & cytopathology, page 2187, volume 2; 2006, CHURCHILL LIVING STONE, ELSEVIER.
10. Norton JA, Le HN. Adrenal tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:1770-1771.
11. Szczeklik A, ed. Choroby wewnętrzne. Tom 1. Kraków, Medycyna Praktyczna, 2006:1143.
12. Justyna Gil, Marta Kalembkiewicz, Edyta Polak, Marta Kostecka-Matyja. Disseminated adrenocortical carcinoma: case report. Pol Arch Med Wewn. 2007; 117 (7): 317-321
13. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91:2027-2037.
14. Sreelatha Chalasani, MD, MPH; Hemender Singh Vats, MD;Tarit K. Banerjee, MD, FACP; and Alan K. Mckenzie, MD. Metastatic Virilizing Adrenocortical Carcinoma:A Rare Case of Cure with Surgery and Mitotane Therapy. Clinical Medicine & Research, Volume 7, Number 1/2: 48-51
15. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003; 138:424-429.
16. Kasperlik-Zaluska AA, Migdalska BM, Makowska, AM. Incidentally found adrenocortical carcinoma. A study of 21 patients. Eur J Cancer. 1988 34, 1721- 1724.
17. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149:273-85.
18. Xichun S, Alberto A, Claudia Y.Castro. Adrenal cortical carcinoma with Concomitant Myelolipoma in a Patient with Hyperaldosteronism .Archives of Pathology and Laboratory Medicine; 129:6.p144-7